The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Basiliximab has been a routine induction therapeutic agent even for well-matched living
kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is
a different drug from cyclosporine, the investigators study the usefulness of
tacrolimus-based immunosuppression without basiliximab in well matched living KT.